07:28 AM EDT, 09/05/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday that two phase 3 trials evaluating once-weekly insulin efsitora alfa in adults with type 2 diabetes achieved their primary endpoint of non-inferior A1C reduction compared with the most frequently used daily basal insulin injections globally.

The company said the QWINT-1 phase 3 trial evaluated efsitora compared with once-daily insulin glargine, while the QWINT-3 trial evaluated efsitora compared with once-daily insulin degludec.

According to Eli Lilly ( LLY ), the trial's topline results also showed that efsitora's overall safety and tolerability profile was "similar" to the daily basal insulin therapies for type 2 diabetes.

Eli Lilly ( LLY ) said detailed results from both trials will be released at an upcoming congress.

Price: 946.46, Change: +0.15, Percent Change: +0.02